Detalhe da pesquisa
1.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638723
2.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716957
3.
Neuroimaging of leptomeningeal myelomatosis: a rare and severe entity.
Ann Hematol
; 101(9): 2091-2092, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35525882
4.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol
; 12: 890376, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924160
5.
Role of parenteral nutrition in cancer patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation.
Tumori
; 91(3): 237-40, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16206647